IDIAZ Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
My Notes
Capture your thoughts, links and company narrative
Idorsia Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.69 |
| 52 Week High | CHF 3.70 |
| 52 Week Low | CHF 0.64 |
| Beta | 1.26 |
| 1 Month Change | -11.66% |
| 3 Month Change | -49.74% |
| 1 Year Change | -66.43% |
| 3 Year Change | -96.28% |
| 5 Year Change | n/a |
| Change since IPO | -95.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDIAZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -49.6% | -5.1% | -2.2% |
| 1Y | -66.4% | -24.5% | 2.4% |
Return vs Industry: IDIAZ underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: IDIAZ underperformed the UK Market which returned 2.4% over the past year.
Price Volatility
| IDIAZ volatility | |
|---|---|
| IDIAZ Average Weekly Movement | 19.6% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: IDIAZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: IDIAZ's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | www.idorsia.com |
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia.
Idorsia Ltd Fundamentals Summary
| IDIAZ fundamental statistics | |
|---|---|
| Market cap | CHF 119.12m |
| Earnings (TTM) | -CHF 296.43m |
| Revenue (TTM) | CHF 74.12m |
1.6x
P/S Ratio-0.4x
P/E RatioIs IDIAZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDIAZ income statement (TTM) | |
|---|---|
| Revenue | CHF 74.12m |
| Cost of Revenue | CHF 186.54m |
| Gross Profit | -CHF 112.41m |
| Other Expenses | CHF 184.01m |
| Earnings | -CHF 296.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -1.57 |
| Gross Margin | -151.66% |
| Net Profit Margin | -399.92% |
| Debt/Equity Ratio | -100.5% |
How did IDIAZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 14:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Idorsia Ltd is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maria Maldonado | Bank Vontobel AG |
| Jean-Philippe Bertschy | Bank Vontobel AG |
| Rosie Turner | Barclays |